---
schema_version: "secwatch.filing_event.v1"
accession: "0001549084-22-000048"
form_type: "8-K"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2022-07-28T23:59:59+00:00"
generated_at: "2026-06-24T07:30:42.460760+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ekso Bionics Q2 revenue up 57% to $3.5M; net loss widens to $3.0M

## Summary
- Revenue $3.5M (+57% YoY); EksoHealth $3.2M, EksoWorks $0.2M; 17 EksoNR units booked.
- Net loss $3.0M ($0.23/share) vs $1.3M loss ($0.10) in Q2 2021; gross margin 47% vs 58%.
- Received FDA 510(k) clearance for EksoNR for Multiple Sclerosis indication.
- Cash $31.9M at June 30, 2022, down from $40.4M at Dec 31, 2021.
- Gain on warrant revaluation $1.0M; R&D expense up 30% YoY on next-gen products.

## SEC filing metadata
- accession: 0001549084-22-000048
- form_type: 8-K
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2022-07-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000154908422000048/0001549084-22-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000154908422000048/ekso-20220728.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549084-22-000048
- JSON: https://secwatch.observer/filing/0001549084-22-000048.json
- Plain text: https://secwatch.observer/filing/0001549084-22-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.